First new drug in years reduces recurrence in high risk HR+ early breast cancer
Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, ...
Sep 20, 2020
0
9